Authors


David Weintritt, MD, FACS

Latest:

Empowering Breast Surgeons: A Call for Collective Action

As survival rates continue to rise for patients with breast cancer, innovations are still needed to advance surgical care for these patients.


Montefiore Einstein Comprehensive Cancer Center

Latest:

Montefiore Einstein Comprehensive Cancer Center Awarded FDA Grant for Clinical Trial on Experimental AML/MDS Treatment

Leading researchers in rare blood cancers to investigate new therapeutic strategy that targets leukemic stem cells.


Idalid Franco, MD, MPH

Latest:

Dr Franco on the Integration of Immunotherapy Treatment in Endometrial Cancer

Idalid Franco, MD, MPH, discusses the use of radiation therapy and immunomodulatory agents in the treatment of endometrial cancer.


Judy Hayek, MD

Latest:

Dr Hayek on Laparoscopic vs Open Surgery in Advanced Ovarian Cancer

Judy Hayek, MD, discusses outcomes with minimally invasive vs open interval complete gross resection in patients with advanced ovarian cancer.


Dejan Juric, MD, Massachusetts General Hospital

Latest:

Future Directions for the Management of HR+ Breast Cancer

Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, share closing thoughts on the current and future treatment landscape for the management of HR+ breast cancer.


Andrew Laccetti, MD, MS

Latest:

Dr Laccetti on PSA Responses With Masofaniten Plus Enzalutamide in mCRPC

Andrew Laccetti, MD, MS, discusses phase 1 findings from a phase 1/2 trial investigating masofaniten in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer.


Anil K. Sood, MD

Latest:

Dr. Sood on Navigating Frontline Maintenance Therapy in Ovarian Cancer

Anil K. Sood, MD, discusses navigating frontline maintenance therapy in ovarian cancer.


Ori Barzilai, MD

Latest:

Overall Survival After Surgery for Spinal Metastases Has Improved Over the Past Two Decades

Postoperative survival after surgery for spinal metastases has improved over the past 20 years, particularly in patients with kidney, breast, lung, and colon tumors metastatic to the spine.


Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB

Latest:

Dr Bal on Updated Findings With BMS-986393 in Relapsed/Refractory Multiple Myeloma

Susan Bal, MD, discusses updated safety and efficacy data from a phase 1 study evaluating the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in relapsed/refractory multiple myeloma, including in patients with prior BCMA-directed therapy.


Nicholas Coupe, MBBS, PhD

Latest:

Dr Coupe on the Background of IMM60 With Pembrolizumab in Melanoma or NSCLC

Nicholas Coupe, MBBS, PhD, discusses the rationale for investigating IMM60 with pembrolizumab in patients with advanced melanoma or metastatic non-small cell lung cancer, as well as key background information that led to this investigation.


Will Pizii

Latest:

A Breakthrough for the “Lab Brat”

Building on research his father conducted decades earlier, Robert Orlowski, MD, PhD, redefined myeloma treatment.


Amanda Blackmon, DO

Latest:

Ongoing Research on MRD Detection May Shift Outcomes for Posttransplant AML

The prediction of relapse following treatment with allogeneic stem cell transplant in patients with acute myeloid leukemia in first complete remission remains an unmet need due to limitations attributed to measurable residual disease detection methods.


Bijal Shah, MD, MS

Latest:

Indirect Comparison of Efficacy of Zanubrutinib Versus Acalabrutinib in the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

The study assessed the comparative efficacy of zanubrutinib vs acalabrutinib in patients with R/R MCL, in the absence of head-to-head clinical trials, using population-adjusted indirect treatment comparison via simulated treatment comparison approach. Data source for the efficacy of zanubrutinib was informed by the pooled individual patient-level data from 2 clinical trials: BGB-3111-206 (NCT03206970) and BGB-3111-AU-003 (NCT02343120). The efficacy of acalabrutinib was informed by the published aggregated data of the ACE-LY-004 trial (NCT02213926).




Georg Lenz, MD

Latest:

Dr. Lenz on the European Approval of Liso-cel in Relapsed/Refractory LBCL

Georg Lenz, MD, discussed the European approval of lisocabtagene maraleucel in relapsed/refractory large B-cell lymphoma.


Iván Márquez Rodas, MD, PhD

Latest:

Dr. Márquez Rodas on the Preliminary Efficacy of BO-112/Pembrolizumab in Advanced Melanoma

Iván Márquez Rodas, MD, PhD, discusses the preliminary results of the phase 2 SPOTLIGHT203 trial, which is evaluating the efficacy and safety of BO-112 plus pembrolizumab in patients with advanced melanoma.


Ellen Ball, ANP-FNP

Latest:

Biomarker Testing Standards-of-Care in Breast and Lung Cancer

The panel shares their recommendations for biomarker testing standard-of-care in breast cancer and lung cancer.


Anurag Agrawal, MD

Latest:

Future Perspectives in the Treatment of Neuroblastoma

Giselle Sholler, MD, and Anurag Agrawal, MD, close their discussion with a look at the future of neuroblastoma treatment, highlighting research being done in areas such as immunotherapies, CAR T-cell therapy, and genomics for more targeted approaches aiming to enhance patient outcomes.


Deborah M. Stephens, DO

Latest:

Optimizing the Treatment of CLL With Novel Therapies

Oncologist-hematologists discuss the outlook for treating patients with chronic lymphocytic leukemia with newer novel therapies.


Pauline Funchain, MD

Latest:

Dr. Funchain on the Rationale for the SWOG S1404 Trial in Melanoma

Pauline Funchain, MD, discusses the rationale for the phase 3 SWOG S1404 trial in high-risk resected melanoma.


Stéphane Champiat MD, PhD

Latest:

Dr. Champiat on Early Efficacy of SOT101 Plus Pembrolizumab in Solid Tumors

Stéphane Champiat MD, PhD, discusses early efficacy seen with the combination of SOT101 and pembrolizumab in solid tumors.


Piotr Rutkowski, MD

Latest:

Dr Rutkowski on the Safety Profile of Avelumab Plus Axitinib in GIST

Piotr Rutkowski, MD, discusses the safety and clinical implications of avelumab in combination with axitinib in unresectable or metastatic GIST


Kara N. Maxwell, MD, PhD

Latest:

Dr Maxwell on Cancer Risk for Males Carrying Germline BRCA Mutations

Kara N. Maxwell, MD, PhD, discusses the risk of cancer for males carrying BRCA mutations.


Logan Roof, MD

Latest:

Dr Roof on Disparities in Lung Cancer Mortality Rates in the United States

Logan Roof, MD, discusses findings from a study investigating trends in lung cancer mortality across different sociodemographic populations and locations in the United States between 1999 and 2020.


Catriona Jamieson, MD, PhD, University of California San Diego

Latest:

Dr. Jamieson on Treatment Considerations in Myelofibrosis

Catriona Jamieson, MD, PhD, discusses treatment considerations for patients with myelofibrosis.


Scott R. Solomon, MD

Latest:

Dr. Solomon on the Rationale For Liso-Cel in Relapsed/Refractory LBCL

Scott R. Solomon, MD, discusses the rationale for examining lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.


Thomas M. Habermann, MD

Latest:

Dr Habermann on Ongoing Trials in MCL and MZL

Thomas M. Habermann, MD, discusses ongoing clinical trials in mantle cell lymphoma and marginal zone lymphoma.


Madappa Kundranda, MD, PhD

Latest:

Leveraging Immunotherapy in GI Malignancies: Looking to the Future

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.


Jean-Philippe Theurillat, MD

Latest:

Dr. Theurillat on Castration and AR Inhibition in Prostate Cancer

Jean-Philippe Theurillat, MD, discusses castration and androgen receptor inhibition in prostate cancer.